The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7462-7469

  Graff, Jeremy R ^a   McNulty, Ann M ^a   Hanna, Kimberly Ross ^a   Konicek, Bruce W ^a   Lynch, Rebecca L ^a   Bailey, Spring N ^a   Banks, Crystal ^a   Capen, Andrew ^a   Goode, Robin ^a   Lewis, Jason E ^a   Sams, Lillian ^a   Huss, Karen L ^a   Campbell, Robert M ^a   Iversen, Philip W ^a   Neubauer, Blake Lee ^a   Brown, Thomas J ^a   Musib, Luna ^a   Geeganage, Sandaruwan ^a   Thornton, Donald ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE; ONCOPROTEIN; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; PROTEIN S6; PROTEIN SERINE THREONINE KINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; XENOGRAFT; ANIMAL; CELL GROWTH; CELL STRAIN HCT116; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; FEMALE; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HCT116 CELLS; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 23844521568     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0071     Document Type: Article

References (26)

1. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001;10:2117-40.
2. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982;257:7847-51.
3. Yoshiji H, Kuriyama S, Ways DK, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999;59:4413-8.
4. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
5. da Rocha AB, Mans DR, Regner A, Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002;7:17-33.
6. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C βII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375-81.
7. Su TT, Guo B, Kawakami Y, et al. PKC-β controls I κ B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3:780-6.
8. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase C βII induces colonie hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711.
9. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP. Protein kinase C (PKC) βII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 2004;279:22118-23. Epub 2004 Mar 22.
10. Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDKl) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEES Lett 2000;484:217-23.
11. 473 phosphorylation by protein kinase Cα in endothelial cells. Cell Signal 2004;16:951-7.
12. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C βII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 2004;279:47720-5. Epub 2004 Sep 09.
13. Aeder SE, Martin PM, Soh JW, Hussaini IM. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 2004;23:9062-9.
14. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 2002;22:2099-110.
15. Goode N, Hughes K, Woodgett JR, Parker PJ. Differential regulation of glycogen synthase kinase-3 β by protein kinase C isotypes. J Biol Chem 1992;267:16878-82.
16. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9.
17. Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett 2003;13:1857-9.
18. Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase C β-selective small molecule. Cancer Chemother Pharmacol 2002;49:69-77.
19. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133-40. Epub 2003 Oct 31.
20. Graff JR, Konlcek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-5.
21. Herbst RS, Thornton DE, Kies MS, et al. Phase 1 study of LY317615, a protein kinase Cβ inhibitor. Proc of ASCO 2002;21:82a.
22. Tenzer A, Zingg D, Rocha S, et al. The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res 2001;61:8203-10.
23. Sansal I, Sellers WH. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.
24. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72.
25. Pore N, Liu S, Shu HK, et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 2004;15:4841-53. Epub 2004 Sep 01.
26. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004;279:45643-51. Epub 2004 Aug 26.